Table 1.

Baseline characteristics of patients and clinical response recieving PD-1^KD BCMA CAR-T cell therapy

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6	Patient 7
Myeloma type	IgDλ	κ	IgG κ	Non-secretory	IgA κ	IgG κ	λ
ISS stage	II	II	II	II	III	III	I
R-ISS	II	II	NA	II	III	NA	II
Time since diagnosis (years)	2.8	4	4	1	2.5	5.5	3.8
High-risk cytogenetics (FISH) at diagnosis	N	del(17 p)	NA	t (11;14), del(17 p)	gain 1q21,t (4;14)	NA	del(17 p)
Prior lines of therapy	4	6	7	7	7	3	6
Alkylating therapy prior to CAR-T(month)	4.3	1	4.5	1.8	2.2	8.4	3.7
Extramedullary Diseases	No	Yes	Yes	Yes	Yes	No	No
Bone marrow plasma cell burden at infusion* (%)	17.8	13.6	1.78	4.7	11.6	11.7	4
BCMA expression† (%)	100	100	96	98.9	99	85	NA
Best response	sCR	SD	sCR	PR	CR	sCR	sCR
CRS grade	Grade 1	–	Grade 2	Grade 3	Grade 2	Grade 2	–

*Bone marrow plasma cell burden at infusion was determined by flow cytometry.

†BCMA expression indicated BCMA surface expression in plasma cells before CAR-T therapy which was determined by flow cytometry.

BCMA, B cell maturation antigen; CRS, cytokine release syndrome; ISS, International Staging System for Multiple Myeloma; NA, not available; PR, partial response; sCR, stringent complete response; SD, stable disease.